Notes - Significant Accounting Policies For Preparation Of Semi-Annual Consolidated Financial Statements
| Concept |
2023-05-01 to 2024-04-30 |
As at 2024-04-30 |
|---|---|---|
| Notes - Significant accounting policies for preparation of semi-annual consolidated financial statements | ||
| Notes - Significant accounting policies for preparation of semi-annual consolidated financial statements | ||
| Disclosure of scope of consolidation | ||
| Number of consolidated subsidiaries and names of major consolidated subsidiaries |
全ての子会社を連結しております。 連結子会社の数 8社 主要な連結子会社の名称 3-D Matrix, Inc. 3-D Matrix Europe SAS. 3-D Matrix Asia Pte. Ltd. 3-D Matrix (Beijing) Biotechnology Co.,Ltd 3-D Matrix Medical Technology Limited 3-D Matrix EMEA B.V. 3-D Matrix UK Limited 3-D Matrix Medical Technology Pty Ltd |
— |
| Number of consolidated subsidiaries | — |
8
xbrli:pure
|
| Disclosure about application of equity method | ||
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method |
非連結子会社及び関連会社がないため、該当事項はありません。 |
— |
| Disclosure about fiscal years, etc. of consolidated subsidiaries |
連結子会社のうち、3-D Matrix (Beijing) Biotechnology Co.,Ltdは12月31日であります。 連結財務諸表の作成に当たっては、連結決算日現在で実施した仮決算に基づく財務諸表を使用しております。なお、その他の連結子会社の事業年度の末日は、連結決算日と一致しております。 |
— |
| Disclosure of accounting policies | ||
| Disclosure of accounting policies | — |